Meet our People

Roberto Lara

Vice President, Global Business Operations and Analytics

Long-standing international CRO authority in the oncology drug development industry. Expertise spanning commercial operations, oncology and clinical operations, partnership development, and investigator networking.

Megan Liles

Vice President, Operational Strategy

Accomplished industry veteran with expertise in the management and execution of global clinical trials across multiple therapeutic areas. Focused on applying innovative strategies to clinical trials to optimize patient identification and recruitment in increasingly niche therapeutic areas.

Eeva Laitinen

Vice President, Clinical Solutions, Project and Clinical Trial Management

Extensive experience in leading international Clinical Trial project teams across Europe and APAC in pharmaceutical industry and CRO environment. Reliable and flexible leader in managing execution of global clinical trials.

Amanda Woodrooffe, PhD

Senior Vice President, General Manager UK Labs

Experienced leader of scientific operations for drug discovery in both the pharmaceutical and CRO industries. Driven to provide actionable data enabling biopharmaceutical research and development. Collaborative partner ensuring licensing and scientific support for corporate development initiatives.

Roz Eijgenhuijsen, PhD

Senior Vice President, Global Regulatory Affairs

Roz Eijgenhuijsen is a strategic leader with specialized expertise in leading regulatory affairs for global drug development and life-cycle management. She has deep experience interacting with the FDA, EMA, and other international regulatory authorities to guide drug development through preclinical to product approval and commercialization. She is dedicated to finding pathways to accelerate the availability of important new medicines to patients.

Renée Deehan, PhD

Vice President, Computational Biology, QuartzBio

Leading authority on developing and applying computational approaches for multiomic biomarker discovery to aid precision medicine development from discovery through the clinic. Strong focus on high definition modeling of the mechanistic underpinnings of drugs and disease through deep biological knowledge. Specialized expertise integrating patient generated health data with molecular biomarkers.

Agnes Pinnel

Senior Vice President, European Solutions

Industry leader in managing large global clinical trials. Co-founder of Argint International, a CRO providing clinical research and regulatory services to the pharmaceutical industry throughout central and south eastern Europe. Holds a masters in biology from Johannes Gutenberg-University in Mainz, Germany.

Alessandro Di Cara, PhD

Senior Director, Europe Lead Biological

Leading expert in flow cytometry and systems biology and senior bioinformatics scientist. Core focus on exploratory immunological biomarker data analyses. Long-standing experience in the pharmaceutical industry. Holds a doctorate in cell biology from Friedrich Miescher Institute in Basel, Switzerland.

Ali Sadighian

Senior Vice President, Business Operations Rare and Orphan Solutions

Accomplished and versatile leader with clinical development and R&D experience gained from academia, biopharma, and several top CROs. Unique skills developed as a laboratory researcher at the UCSD School of Medicine, in quality control in the biotech industry, in clinical operations, and as a senior executive. Dedicated to helping innovative companies bring new therapies to patients and families in greatest need.

Andrea Cotton-Berry, MSc

Global Head of Strategic Development, Clinical Solutions

Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.

Angelina Bisconte

Senior Director, Translational Biology & Biomarker Development

Authority in utilizing human primary biological tissue and cells in research and drug discovery. Developer of translational biomarkers for Phase I/II clinical programs in autoimmunity, inflammation and cancer. Expert in phenotypic cell-based assays using multiple primary cell systems such as T/Th17/T-regs, NK-T, B/Plasma/Plasmablasts, Myeloid cells, Dendritic cells (pDCc/mDCs), and MDSCs. Strategist in multi-parametric single-cell flow cytometry and analysis of flow cytometry data. Broad network of contacts at clinical sites and research hospitals, experienced with IRB submissions and clinical protocols. Scientific leader for Precision’s Biomaterials commercial sourcing.

Chad Clark

President

Recognized industry leader focused on combining cutting-edge technology, strategic program design, and operational excellence to help life sciences companies effectively address the increasing evidence demands and need to accelerate research initiatives. Previous experience spans the execution of phase I-IV clinical trials, specialty lab services, biospecimen logistics and banking, risk management, and patient support initiatives.

Cullen Taylor, MD

Medical Director, Biospecimen Solutions

Visionary dedicated to enabling collaborations that help facilitate efficient translational research, discovery and development. Full-time pathologist and founder of the uniquely consultative biospecimens company Glas. Believes that forward-thinking pathologists and laboratorians should play a critical role in realizing the promise of translational medicine.

Darren Davis, PhD

Senior Vice President

Visionary leader with more than 25 years of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases.

David Parker, PhD

Senior Vice President, Diagnostics Solutions

Strategic visionary and healthcare industry veteran operating at the intersection of reimbursement, health economics, clinical science, and marketing strategy. Expertise encompasses all aspects of market access, reimbursement, and evidence development strategy, with a particular focus on personalized medicine, advanced molecular and companion diagnostics, and targeted therapies. Has launched successful products, guided major investment and acquisition decisions, and driven favorable coverage and payment determinations by public and private payers alike. Speaker and author.

Deborah Phippard, PhD

Senior Vice President, Research Services

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Elizabeth Ludington, PhD

Senior Vice President, Biometrics Rare and Orphan Solutions

Seasoned veteran of the pharmaceutical and biotech industries both through CROs and sponsor companies. Provides statistical, technical, and strategic expertise for preclinical studies, INDs, Phase I-IV clinical studies, eCTDs, and postmarketing studies. Statistical expertise includes study design, protocol review, and writing and reviewing analysis plans and statistical reports. Skilled at representing clients at meetings with regulatory authorities, and as a statistical consultant for programs at all phases of development.

Gerald Messerschmidt, MD, FACP

Chief Medical Officer, Clinical Solutions

Oncologist, hematologist and veteran expert in clinical research, clinical practice and development of pharmaceuticals, biologic products and immune modulation therapies. Primary consultant to the Moonshot 2020 program and an authority in optimizing clinical trial designs to accelerate product approval. Significant experience and credibility with the FDA as well as regulatory authorities in Europe, Japan and other countries.

Jared Kohler, PhD

Senior Vice President, Operations & Customer Solutions

Extensive industry expertise across the pharmaceutical and biotech space-translational research, data management, and statistical support-with a focus in precision medicine-guided efforts in drug and diagnostic development. Subject matter expert in genomics. Pioneered approaches in biomarker data management and has led Biometrics operations on over 70 clinical studies.

Jay Lezcano

Senior Vice President, Business Development

Clinical research veteran with a focus on strategic initiatives in the laboratory and biospecimen arena. Dedicated to helping pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products.

Jesus Garcia, PhD

Scientific Liaison

Respected scientist and research investigator with expertise spanning biotechnology, medical science, technology development, and data analysis. Partners cross-functionally to identify and advance projects related to validation studies, method development, and reference standards.

Jim Boushell

Vice President, Biospecimen Solutions

Pioneer in the field of biospecimen procurement and co-founder of ProMedDx. Leader in the delivery of services for organizations in the biotechnology industry, including clinical study support and biostorage. Experienced executive with a demonstrated career of building innovative patient-centric biotech clinical programs. Focused on addressing the growing need for highly annotated, regulatory-compliant human biospecimens by the life science research communities.

Jim Sperzel

Vice President, Biospecimen Solutions

Long-standing leader in the life sciences and in-vitro diagnostics industries. Co-founder of ProMedDx, a full suite of biospecimen solutions connecting biopharma teams to 1000s of clearly stratified and annotated cohorts. Expertise spanning operations, finance, human resources, government grant applications, and corporate strategy.

Joseph Bower, PhD, MBA

Senior Vice President, Laboratory Operations

Experienced senior leader spanning the academic, pharmaceutical, and CRO industries. Specific expertise in biotherapeutics and vaccines for preclinical and clinical development programs and in identifying the appropriate immunochemistry assays for new development programs. Broad record of accomplishment leading global teams, delivering business strategies, developing business, and ensuring operational excellence.

Julia Amo, MBA, PMP

Chief Operating Officer, Oncology Solutions

Expert strategist for the pharmaceutical, CRO, and healthcare industries. Offers extensive multi-disciplinary drug development experience at the project, compound, and portfolio levels. Takes a sophisticated approach to the operations, infrastructure, and growth of Precision’s oncology division.

Karen Richards, RAC

Senior Vice President, In Vitro Diagnostics and Quality

Leader and innovator in the GMP/ISO/FDA/EU-regulated in vitro diagnostic (IVD) industry. Spearheads regulatory approvals worldwide for both novel and traditional IVD assays and products, as well as laboratory developed tests in the United States. Builds ground-up quality systems, meeting the requirements of US FDA, ISO 13485, CLIA, and CAP.

Karl Forner, MSc

Senior Director, Europe Lead Informatics

Respected expert in mathematics and fundamental and theoretical computer science. Strong focus on genetics. Developer of innovative bioinformatics algorithms for SNP analyses and genome-wide association studies. Avid proponent of and proactive contributor to the open source community.

Marc Lamarine, PhD

Senior Director, Europe Lead Operations

Distinguished expert in the analysis of large-scale, high-throughput genomics and genetics data. Statistical programmer combining computational and experimental methods in various therapeutic areas, including oncology and autoimmune disease.

Matthew Hall, PhD

Senior Director, Business Development

Influential strategy expert in end-to-end bioinformatics and artificial intelligence solutions for biomarker-guided drug development, maximizing the value and utility of biomarker data in clinical trials, CDx, and diagnostics. Previously CEO of SimplicityBio. Holds a doctorate in molecular and cellular biology from the University of Lausanne.

Patricia Devitt Risse, PharmD

President, Clinical Solutions

Widely respected industry leader and founder of ACT Oncology. Guides strategic protocol design and study optimization on behalf of sponsors. Has extensive experience in Phase I-IV trials for most indications, including solid tumor and hematologic malignancies. Leads integrated teams to combine the strength of biomarker insights with clinical outcome data to optimize the development pathway.

Patricia Terek, MSc

Senior Director, Business Development, Oncology Solutions

30+ year healthcare industry veteran bridging business development efforts and program implementation for optimal client satisfaction. Serves as the primary business development contact for biotech and pharmaceutical clients on the west coast.

Pedro Faustino, MBA

Senior Director, Client Solutions

Industry leader with deep expertise in healthcare technology focused on using artificial intelligence to help biopharma and diagnostic companies solve the question, “Which therapy, when, and for which patient?” Extensive industry knowledge across the pharmaceutical and biotech space—translational informatics, biomarker R&D. Holds an MBA and is passionate about exploring interfaces between people and technology for effective communication.

Rob Fannon, MPH, MBA

General Manager, Biospecimen Solutions

Respected vetran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Masters of Business Administration from the Johns Hopkins University.

Robert Ott, MBA

Senior Vice President, Business Operations

Vetran with deep knowledge of the contract research/pharmaceutical services industry. Provides project leadership and executive support to clients. Directs operational functions, resourcing, and business strategy internally, structuring oncology operations to match client needs.

Sanjay Garg, PhD

Senior Director, Business Development

Research professional in both academia and industry, focused on bringing immune monitoring services to autoimmunity and tumor-immunology clinical trials. Specialist in innate and adaptive immunity, immunoassay development, onco-immunology, autoimmunity, target validation and preclinical biomarker discovery, and workflow and SOP design.

Scott Marshall, PhD

Managing Director, Translational Informatics and Diagnostic Sciences

Industry expert, leading regulatory submissions, translational informatics, and biomarker R&D for pharmaceutical and biotechnology companies. Focus on precision medicine-guided efforts, strategy, and medical device/diagnostic development. Global responsibility for translational informatics R&D efforts. Has led the development of novel methodologies for patient stratification and biomarker guided clinical trial design.

Sean Pintchovski, PhD

Director, Neurology Solutions

Trusted leader driving multi-site research programs that leverage proprietary state-of-the-art technologies to identify, validate, and integrate next-generation biomarkers to advance clinical trials for a wide range of neurological indications. Able to generate novel hypotheses, then identify and develop the right methods to answer the right scientific questions.

Steve Dobbin

Senior Vice President, European Solutions

Industry leader with expertise managing large multinational clinical trials in 20+ countries across Europe, North America and APAC. Dedicated to providing quality, flexible and cost-effective solutions for clinical development programs.Co-founder of Argint International, a full-service CRO for phase I-IV clinical research trials. Holds a degree in microbiology from University of Warwick, United Kingdom.

Sven Olek, PhD

Senior Vice President, Research

Inventor, industry expert, founder and leader of Epiontis. Developed the patents forming the basis of Epiontis’s intellectual property. Conducted pre- and postdoctoral research at the Center for Molecular Biology and Biomedicine (ZMBH) of the University of Heidelberg, Germany, and the R.W. Johnson Pharmaceutical Research Institute, San Diego, California, USA. Received a BSc from the Imperial College of Science, Technology, and Medicine, London, and a PhD in Biochemistry from the University of London.

Tobias Guennel, PhD

Senior Vice President, Product Development & Systems Integration

Distinguished expert working across the pharmaceutical and biotech space, leading regulatory submissions, translational informatics, and biomarker R&D. Clear focus on precision medicine-guided efforts, strategy, and medical device/diagnostic development. Led numerous analytical R&D efforts and developed novel methodologies to harmonize and analyze data from high-throughput assays, translating it to value at the patient level.

Ulrich Hoffmueller, PhD, MBA

Vice President Immune Monitoring Solutions

Veteran biochemist, industry expert, cofounder of Epiontis. Holds a Master’s in Biochemistry from Humboldt University, a PhD from the Charité University Clinic receiving the Charité Research Award, and an MBA from the Berlin School of Economics and Law, Berlin, Germany.

Al Blunt, MD

Senior Vice President, Medical

Noted authority in the drug development industry. Sought-after strategist providing guidance for and oversight of the design, conduct, and analysis of oncology trials, and hands-on leadership for Precision’s team of oncology medical monitors. Expertise honed in clinical trials from phase 1-3 for a wide variety of anticancer drug classes and cancer types.

Tina Patel, MS, MBA

Senior Director, Business Development

Healthcare industry veteran serving as the primary business development contact for life sciences clients in New England. Strategist focused on biomarker laboratory solutions for clinical trials across diverse indications. Holds a Master’s in Business Administration from Babson College and a Master of Science from Boston University.

Teresa Pokladowski, MS

Senior Director, Clinical Business Solutions

Respected business development strategist, building successful clinical programs for clients in Massachusetts. Innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Experienced in executing phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management.

Ted Foss, PhD

Senior Director, Biomarker Data Management Systems & Data Integration

Expert in multi-modal data management and analysis, with an extensive background in clinical NGS data. Deep experience developing methods across wide range of commercial, service, and operational verticals in biotech and clinical settings. Holds a doctorate in Biophysics from The Scripps Research Institute.

Tania Wiens, MSc., MBA

Senior Director, Business Development

Biotechnology industry veteran with dual emphasis on research and business and a focus on translational sciences. Expertise spans biomarkers, oncology and rare disease, diagnostics, and translational medicine. Holds a Master’s in Veterinary Microbiology from the University of Saskatchewan, and an MBA from San Jose State University.

Stephen Rundlett, PhD

Vice President, Bioanalytical Services

Dynamic and diverse experience leading scientific, operational, marketing, and sales efforts for drug development programs. Specialist in the development and oversight of ligand binding and cell-based assays supporting immunogenicity, phamacokinetics, pharmacodynamic biomarkers and neutralizing antibody assessments.

Rachel Owen, PhD

Vice President, Immunology

Trusted global leader in immune-oncology and infectious disease research. Deep expertise in flow cytometry assay development, cell-based assays and biomarker discovery, clinical sample testing, and validation for early and late phase clinical trials. Client-facing strategist for translational studies.

Mairead Kehoe

Executive Vice President, Clinical Solutions

Veteran strategist and industry leader, with experience spanning all aspects of global clinical development for biotech, CRO and biopharma clinical research. Expert in end-to-end drug development operations, from early development through product approval.

Kennon Daniels, PhD

Senior Director, In Vitro Diagnostics and Quality

Scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms.

Katerina Kaleova, MD

Medical Director, Clinical Operations

Leading physician with deep experience in clinical operations and medical monitoring management for phase 1-3 studies across indications, including onco-hematological, rare, cardiological, dermatological, and pulmonological disease trials. Noted medical strategist with excellent understanding of the complete drug development process.

Frances Murphy LLB (Hons)

Senior Director of Clinical Business Solutions, EU & APAC

Leading authority in clinical CROs, focused on client services and regional growth implementation. Dedicated proponent of harnessing truly personalized medicine to develop more effective treatments for patients. Brings that passion to client support.

Etleva Pashaj, MD

Vice-President, Medical

Strategic, innovation-driven, drug discovery veteran—and board-certified oncologist—with extensive international (EMA and FDA) regulatory experience. Record of excellence in clinical development, medical monitoring and medical strategy, and managing and mentoring cross-functional and global teams for phase 1-4 onco-hematology studies.

Crystal Sung, PhD

Sr. Director, Cell & Gene Therapy Analytical CDx Services

Respected scientist and bioanalytical leader focused on clinical development of companion diagnostics for rare diseases and oncology. American board-certified medical laboratory immunologist. Holds a CLIA high complexity/New York State lab director’s qualification in Diagnostic Immunology and Clinical Chemistry.

Cliff Culver

Senior Vice President, QuartzBio

Experienced strategist specializing in the development of technology-enabled solutions for the life science industry. Authority in maximizing the value of complex biomarker data and increasing the efficiency of research & development operations. Expertise with rapidly scaling technology-enabled businesses.

Clare Sarvary Fourrier

Senior Vice President, Global Operational Strategy

Veteran of global oncology clinical operations, with in-depth experience in phase 1-3 oncology and hematology research as well as early-phase studies. Builder of world-class oncology research teams and leader of strategic growth of resources and operations across Europe. Keenly focused on study delivery, mitigation of study risk, and client service.

Chris Ellis

Senior Director, Clinical Business Solutions

Seasoned business development expert dedicated to working creatively within sponsors’ operational and financial parameters to bring new oncology and rare disease treatments to patients. Track record in establishing productive long-term relationships. Managed international oncology clinical operations teams, sales and marketing, and laboratory research.

Angélique Heckmann, PhD

Senior Director, Translational Business Solutions, Europe & APAC

Passionate leader combining a scientific background in immunology with significant business development experience. Expert at supporting pre-clinical research and biomarker data analysis. Committed to balancing science, team coordination, and communication to achieve excellence in project delivery and accelerate oncology drug development programs.

Amanda Napier

Senior Director, Global Program Management Translational & Lab Services

Industry veteran with deep expertise in large phase 3, open label and post marketing trials. Adept at managing potential execution and delivery constraints, working across teams globally to ensure that projects remain within the established timelines and budgets.

Veteran expertise from industry leaders in clinical trials, translational sciences and transformative data

Meet our People

Veteran expertise from industry leaders in clinical trials, translational sciences and transformative data

Al Blunt, MD

Alessandro Di Cara, PhD

Amanda Napier

Amanda Woodrooffe, PhD

Andrea Cotton-Berry

Angelina Bisconte

Angélique Heckmann, PhD

Chad Clark

Chris Ellis

Clare Sarvary Fourrier

Cliff Culver

Crystal Sung, PhD

Cullen Taylor, MD

Darren Davis, PhD

David Parker, PhD

Deborah Phippard, PhD

Eeva Laitinen

Elizabeth Ludington, PhD

Etleva Pashaj, MD

Frances Murphy LLB (Hons)

Gerald Messerschmidt, MD, FACP

Jared Kohler, PhD

Jay Lezcano

Jesus Garcia, PhD

Jim Boushell

Jim Sperzel

Joseph Bower, PhD, MBA

Julia Amo, MBA, PMP

Karen Richards, RAC

Karl Forner, MSc

Katerina Kaleova, MD

Kennon Daniels, PhD

Mairead Kehoe

Marc Lamarine, PhD

Megan Liles

Patricia Terek, MSc

Pedro Faustino, MBA

Rachel Owen, PhD

Renée Deehan, PhD

Rob Fannon, MPH, MBA

Robert Ott, MBA

Roberto Lara

Roz Eijgenhuijsen, PhD

Sanjay Garg, PhD

Scott Marshall, PhD

Stephen Rundlett, PhD

Steve Dobbin

Sven Olek, PhD

Tania Wiens, MSc., MBA

Teresa Pokladowski, MS

Tina Patel, MS, MBA

Tobias Guennel, PhD

Ulrich Hoffmueller, PhD, MBA

Work with an unrivalled team of experts

Work with an unrivalled team of experts